Publication | Open Access

The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) α-308 G/G promoter polymorphism

ImmunologyPathologyImmunotherapyImmune-related Gene PolymorphismInflammatory ArthritisInflammationRheumatoid DisorderTumor Necrosis FactorInflammatory Rheumatic DiseaseAutoantibodiesAnti-citrullinated Protein AntibodiesRheumatoid ArthritisRheumatologyAutoimmune DiseaseRheumatic DiseasesImmune SurveillanceAutoimmunityRa PatientsMedicine